Drug Trial Radar · NCT06693843
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
230
Actual
Start
Oct 28, 2024
Primary completion
Oct 24, 2025
Study completion Jul 9, 2026
Sponsor
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at least one weight-related comorbidity. Participants will be randomized to aleniglipron or placebo in a ratio of 3:1 within each Cohort receiving multiple-ascending, QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 36 weeks of treatment. At the end of the study (after completing 36 weeks of treatment), participants will be offered to continue with an open-label extension (OLE) where they will receive aleniglipron for an additional 36 weeks.
Conditions
- Obesity, Overweight, or Chronic Weight Management
Interventions
Aleniglipron or PlaceboDrug
Drug: Aleniglipron Administered orally Drug: Placebo Administered orally
Aleniglipron or PlaceboDrug
Drug: Aleniglipron Administered orally Drug: Placebo Administered orally
Aleniglipron or PlaceboDrug
Drug: Aleniglipron Administered orally Drug: Placebo Administered orally
AleniglipronDrug
Drug: Aleniglipron Administered orally
AleniglipronDrug
Drug: Aleniglipron Administered orally
AleniglipronDrug
Drug: Aleniglipron Administered orally
AleniglipronDrug
Drug: Aleniglipron Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in body weight from Baseline to Week 36Time frame: Baseline and week 36
- TEAEs and SAEsTime frame: Baseline and week 72
- AESITime frame: Baseline and week 72
- Evaluate the safety and tolerability of participants with abnormal laboratory values, including hematology, serum chemistry, and coagulationTime frame: Baseline and week 72
- Evaluate long-term safety and tolerability of aleniglipron as measured through electrocardiograms (including, but not limited to, the measurements of ventricular HR, PR interval, QRS duration, QT interval, and QTcF)Time frame: Baseline and week 72
- Evaluate the safety and tolerability of participants with abnormal vital signs, including blood pressure, heart rate, and temperatureTime frame: Baseline and week 72
Locations
39 sites in 1 country. Site status is shown where the registry gives one.
ACCESS Research Site
Phoenix, Arizona
ACCESS Research Site
Anaheim, California
ACCESS Research Site
Los Angeles, California
ACCESS Research Site
Montclair, California
ACCESS Research Site
Rancho Cucamonga, California
ACCESS Research Site
Sacramento, California
ACCESS Research Site
Spring Valley, California
ACCESS Research Site
Honolulu, Hawaii
ACCESS Research Site
Chicago, Illinois
ACCESS Research Site
Chicago, Illinois
ACCESS Research Site
Evanston, Illinois
ACCESS Research Site
Muncie, Indiana
ACCESS Research Site
Valparaiso, Indiana
ACCESS Research Site
West Des Moines, Iowa
ACCESS Research Site
Baton Rouge, Louisiana
ACCESS Research Site
Richfield, Minnesota
ACCESS Research Site
City of Saint Peters, Missouri
ACCESS Research Site
Hazelwood, Missouri
ACCESS Research Site
Springfield, Missouri
ACCESS Research Site
Albany, New York
ACCESS Research Site
Binghamton, New York
ACCESS Research Site
Brooklyn, New York
ACCESS Research Site
Rochester, New York
ACCESS Research Site
Wilmington, North Carolina
ACCESS Research Site
Cincinnati, Ohio
ACCESS Research Site
Norman, Oklahoma
ACCESS Research Site
Medford, Oregon
ACCESS Research Site
Pittsburgh, Pennsylvania
ACCESS Research Site
Moncks Corner, South Carolina
ACCESS Research Site
Chattanooga, Tennessee
ACCESS Research Site
Austin, Texas
ACCESS Research Site
Austin, Texas
ACCESS Research Site
Dallas, Texas
ACCESS Research Site
Dallas, Texas
ACCESS Research Site
Mesquite, Texas
ACCESS Research Site
Shavano Park, Texas
ACCESS Research Site
West Jordan, Utah
ACCESS Research Site
Winchester, Virginia
ACCESS Research Site
Morgantown, West Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.